| 1. Select homogenous patients with inflammatory variants (arthritis and cutaneous manifestations) |
| 2. Evaluate potential renal protective effects |
| 3. Evaluate the effect on SLE related metabolic syndrome |
| 4. Evaluate the effect on cardiovascular (CV) morbidity and mortality |
| 5. Evaluate an anti-osteoclastogenic property |
| 6. Evaluate its value as a glucocorticoid sparing agent (will have protective effect on metabolic syndrome, CV morbidity and osteoporosis) |
| 7. Cost advantage over newer agents |
| 1. Select homogenous patients with inflammatory variants (arthritis and cutaneous manifestations) |
| 2. Evaluate potential renal protective effects |
| 3. Evaluate the effect on SLE related metabolic syndrome |
| 4. Evaluate the effect on cardiovascular (CV) morbidity and mortality |
| 5. Evaluate an anti-osteoclastogenic property |
| 6. Evaluate its value as a glucocorticoid sparing agent (will have protective effect on metabolic syndrome, CV morbidity and osteoporosis) |
| 7. Cost advantage over newer agents |
| 1. Select homogenous patients with inflammatory variants (arthritis and cutaneous manifestations) |
| 2. Evaluate potential renal protective effects |
| 3. Evaluate the effect on SLE related metabolic syndrome |
| 4. Evaluate the effect on cardiovascular (CV) morbidity and mortality |
| 5. Evaluate an anti-osteoclastogenic property |
| 6. Evaluate its value as a glucocorticoid sparing agent (will have protective effect on metabolic syndrome, CV morbidity and osteoporosis) |
| 7. Cost advantage over newer agents |
| 1. Select homogenous patients with inflammatory variants (arthritis and cutaneous manifestations) |
| 2. Evaluate potential renal protective effects |
| 3. Evaluate the effect on SLE related metabolic syndrome |
| 4. Evaluate the effect on cardiovascular (CV) morbidity and mortality |
| 5. Evaluate an anti-osteoclastogenic property |
| 6. Evaluate its value as a glucocorticoid sparing agent (will have protective effect on metabolic syndrome, CV morbidity and osteoporosis) |
| 7. Cost advantage over newer agents |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
